0001140361-23-054514.txt : 20231122
0001140361-23-054514.hdr.sgml : 20231122
20231122192722
ACCESSION NUMBER: 0001140361-23-054514
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231030
FILED AS OF DATE: 20231122
DATE AS OF CHANGE: 20231122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GNI Group Ltd.
CENTRAL INDEX KEY: 0001958461
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51173
FILM NUMBER: 231434783
BUSINESS ADDRESS:
STREET 1: NIHONBASHI-HONCHO YS BLDG 3F
STREET 2: 2-2-2 NIHONBASHI-HONCHO, CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 103-0023
BUSINESS PHONE: 81-3-6214-3600
MAIL ADDRESS:
STREET 1: NIHONBASHI-HONCHO YS BLDG 3F
STREET 2: 2-2-2 NIHONBASHI-HONCHO, CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 103-0023
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GNI USA, Inc.
CENTRAL INDEX KEY: 0001973229
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51173
FILM NUMBER: 231434782
BUSINESS ADDRESS:
STREET 1: 12730 HIGH BLUFF DRIVE
STREET 2: SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-284-0324
MAIL ADDRESS:
STREET 1: 12730 HIGH BLUFF DRIVE
STREET 2: SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GYRE THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001124105
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 562020050
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (619) 949-3681
MAIL ADDRESS:
STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: CATALYST BIOSCIENCES, INC.
DATE OF NAME CHANGE: 20150820
FORMER COMPANY:
FORMER CONFORMED NAME: TARGACEPT INC
DATE OF NAME CHANGE: 20000919
4
1
form4.xml
X0508
4
2023-10-30
0001124105
GYRE THERAPEUTICS, INC.
GYRE
0001958461
GNI Group Ltd.
NIHONBASHI-HONCHO YS BLDG 3F
2-2-2 NIHONBASHI-HONCHO, CHUO-KU
TOKYO
M0
103-0023
JAPAN
true
0001973229
GNI USA, Inc.
12730 HIGH BLUFF DRIVE
SUITE 250
SAN DIEGO
CA
92130
true
false
Common Stock
2023-10-30
4
J
0
63588119
A
64005887
I
See Remarks
Represents the number of shares of common stock of the Issuer received by the Reporting Person in exchange for the shares of Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares ("CPI") and Further Challenger International Limited, a company incorporated and existing under the laws of the British Virgin Islands with company number 1982271, held by the Reporting Person pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the "Business Combination Agreement"), by and among Catalyst Biosciences, Inc., a Delaware corporation,
[cont'd from FN 1] GNI USA, Inc., a Delaware corporation ("GNI USA"), the Reporting Person, GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China, the Minority Holders (as defined therein) and CPI. Pursuant to the terms of the Business Combination Agreement, on October 30, 2023, the Issuer acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China.
These securities are held by GNI USA which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA.
/s/ Branden Berns, as attorney-in-fact for GNI Group Ltd.
2023-11-22
/s/ Branden Berns, as attorney-in-fact for GNI USA, Inc.
2023-11-22